Document ID: chunk:federal_register_of_legislation:F2025C00158:clause:4_1:p31
Version: federal_register_of_legislation:F2025C00158
Segment Type: clause
Provision Reference: sch 4 cl 1 (pt 31/381)
Character Range: 11680335–11690014

than 4 weeks from cessation of the most recent course of biological medicine. It is recommended that an application for the continuing treatment be submitted no later than 4 weeks from the date of completion of the most recent course of treatment. This is to ensure treatment continuity for those who meet the continuing restriction.
                                                                                                                                                                    Where a response assessment is not conducted within the required timeframe, the patient will be deemed to have failed to respond to treatment with this drug, unless the patient has experienced a serious adverse reaction of a severity resulting in the necessity for permanent withdrawal of treatment.
                                                                                                                                                                    If a patient fails to demonstrate a response to treatment with this drug under this restriction they will not be eligible to receive further PBS-subsidised treatment with this drug for this condition within this treatment cycle.
C10858              P10858         CN10858          Morphine                                                                                                        Chronic severe disabling pain                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             Compliance with Authority Required procedures
                                                                                                                                                                    Initial PBS treatment after 1 June 2020 where patient has been treated with opioids for more than 12 months
                                                                                                                                                                    The condition must require daily, continuous, long term opioid treatment; AND
                                                                                                                                                                    Patient must have cancer pain.  or
                                                                                                                                                                    Patient must have had or would have inadequate pain management with maximum tolerated doses of non-opioid or other opioid analgesics.  or
                                                                                                                                                                    Patient must be unable to use non-opioid or other opioid analgesics due to contraindications or intolerance.
                                                                                                                                                                    Palliative care nurses may conduct annual review under this item for the treatment of palliative care patients only.
C10859              P10859         CN10859          Hydromorphone                                                                                                   Severe pain
                                                                                                                                                                    Patient must have had or would have inadequate pain management with maximum tolerated doses of non-opioid and other opioid analgesics.  or
                                                    Morphine                                                                                                        Patient must be unable to use non-opioid and other opioid analgesics due to contraindications or intolerance.

C10860              P10860         CN10860          Oxycodone                                                                                                       Severe pain
                                                                                                                                                                    The treatment must be for post-operative pain following a major operative procedure; AND
                                                                                                                                                                    Patient must have had or would have inadequate pain management with maximum tolerated doses of non-opioid analgesics.  or
                                                                                                                                                                    Patient must be unable to use non-opioid analgesics due to contraindications or intolerance.
C10863              P10863         CN10863          Apomorphine                                                                                                     Parkinson disease                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         Compliance with Authority Required procedures - Streamlined Authority Code 10863
                                                                                                                                                                    Patient must have experienced severely disabling motor fluctuations which have not responded to other therapy; AND
                                                                                                                                                                    The treatment must be commenced in a specialist unit in a hospital setting.
C10889              P10889         CN10889          Guselkumab                                                                                                      Severe chronic plaque psoriasis                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           Compliance with Written Authority Required procedures
                                                                                                                                                                    Continuing treatment, Face, hand, foot
                                                    Tildrakizumab                                                                                                   Patient must have received this drug as their most recent course of PBS-subsidised biological medicine treatment for this condition; AND
                                                                                                                                                                    Patient must have demonstrated an adequate response to treatment with this drug; AND
                                                                                                                                                                    The treatment must be as systemic monotherapy (other than methotrexate); AND
                                                                                                                                                                    Patient must not receive more